References

: 1. Plan cancer 2015-2019. http://www.sante. gov.dz 2. M. T. Abad. «Enquête épidémiologique de la maladie de Hodgkin 1996-2005». RAH, 1, Sept 2009 3. M. T. Abad. «Epidémiologie de la maladie de Hodgkin en Algérie période : 2008-2012», congrès SAHTS 2014. 4. S. M. Ansell. Hodgkin lymphoma : 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91:434442. 5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hodgkin Lymphoma v3.2018. 2018. Available athttps://www.nccn.org/professionals/ physician_gls/pdf/hodgkins.pdf. Accessed July 1, 2018. 6. Annuaire 2015 SAHTS. www.sahts-dz. com 7. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma : consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571-578. 8. Oki Y, Chuang H, Chasen B, et al. «The prognostic value of interim positron emissiontomography scan in patients with classical Hodgkin lymphoma». Br J Haematol. 2014;165(1) : 112-116. 9. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progressionfree survival in Hodgkin lymphoma. Blood. 2006 ; 107(1) : 52-59. 10. Johnson P, Federico M, Kirkwood A, et al. Adapted Treatment Guided by Interim PETCT Scan in Advanced Hodgkin’s Lymphoma. N Engl J Med. 2016;374(25):24192429. doi : 2410.1056/NEJMoa1510093. 11. B. von Tresckow and C. H. Moskowitz. «Treatment of relapsed and refractory Hodgkin lymphoma». Semin Hematol. 2016;53:180-185. 12. A. Stamatoullas, P. Brice, M. S. Gueye, et al. Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin’s lymphoma : a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC). Bone Marrow Transplant. 2016 ; 51 : 928-932. 13. N. Schmitz, B. Pfistner, M. Sextro, et al. «Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease : a randomised trial». Lancet. 2002;359:2065-2071. 14. S. M. Bair, L. Strelec, S. J. Nagle, et al. Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: a retrospective analysis. Am J. Hematol. 2017 ; 92 : 879-884. 15. M. A. Elshenawy, M. Shahzad Rauf, T. A. M. Elhassan, I. Maghfoor and S. Akhtar. «Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant». Ann Hematol. 2018 ; 97 : 1229-1240. 16. R. Horie and T. Watanabe. CD30 : expression and function in health and disease. Semin Immunol. 1998 ; 10 : 457-470. 17. Connors JM, Jurczak W, Straus DJ, et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma. N Engl J Med. 2018 ; 378(4) : 331-344. 18. Ramchandren R, Advani RH, Ansell SM, et al. Brentuximab Vedotin Plus Chemotherapy in North American Patients with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Clin Cancer Res. 2019. Ramchandren R, Domenech ED, Rueda A, et al. Checkmate 205 Cohort D : «A Phase 2 trial of nivolumab for newly diagnosed advanced-stage classical Hodgkin lymphoma». European Haematology Association. Stockholm, Sweden ; 2018.